Lario Therapeutics, an Edinburgh, Scotland, UK-based biopharmaceutical company developing precision medicines for epileptic and neurological disorders, received a $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
The company intends to use the amount to supports preclinical research of its CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson’s disease.
The program is conducted in collaboration with the Oxford Parkinson’s Disease Centre, which will also be delivering key science as part of the grant.
Led by CEO Henning Steinhagen, and CSO Tom Otis, Ph.D., Professor of Neuroscience UCL, Lario Therapeutics is developing precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease. Its pipeline begins with genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders.
FinSMEs
22/07/2024